| Literature DB >> 24333896 |
Linda P O'Reilly1, Cliff J Luke1, David H Perlmutter1, Gary A Silverman1, Stephen C Pak2.
Abstract
Caenorhabditis elegans has been proven to be a useful model organism for investigating molecular and cellular aspects of numerous human diseases. More recently, investigators have explored the use of this organism as a tool for drug discovery. Although earlier drug screens were labor-intensive and low in throughput, recent advances in high-throughput liquid workflows, imaging platforms and data analysis software have made C. elegans a viable option for automated high-throughput drug screens. This review will outline the evolution of C. elegans-based drug screening, discuss the inherent challenges of using C. elegans, and highlight recent technological advances that have paved the way for future drug screens.Entities:
Keywords: Clozapine (PubChem CID: 2818); Drug target identification; Fluphenazine (PubChem CID: 3372); High-throughput screening; Human disease models; Nemadipine-A (PubChem CID: 2856102); Pharmaceuticals; Phenotypic analysis; Small molecules; Whole organism model
Mesh:
Year: 2013 PMID: 24333896 PMCID: PMC4019719 DOI: 10.1016/j.addr.2013.12.001
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470